Pentoxifylline for anemia in chronic kidney disease: A systematic review and meta-analysis

PLoS ONE

Volumn 10, Issue 8, 2015, Pages

  Bolignano, Davide ^a   D'Arrigo, Graziella ^a   Pisano, Anna ^a   Coppolino, Giuseppe ^b  

^a CNR   (Italy)

^b University Hospital   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANEMIC AGENT; FERRITIN; HEMOGLOBIN; HEPCIDIN; IRON; PENTOXIFYLLINE; PLACEBO; TRANSFERRIN; ANTIINFLAMMATORY AGENT; PHOSPHODIESTERASE INHIBITOR;

ANEMIA; ARTICLE; CASE CONTROL STUDY; CHRONIC KIDNEY DISEASE; DIALYSIS; DIET SUPPLEMENTATION; DISEASE ASSOCIATION; END STAGE RENAL DISEASE; FERRITIN BLOOD LEVEL; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEMATOCRIT; HUMAN; IRON BINDING CAPACITY; IRON BLOOD LEVEL; META ANALYSIS; PERITONEAL DIALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL REPLACEMENT THERAPY; RISK FACTOR; SYSTEMATIC REVIEW; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; ADULT; CHRONIC KIDNEY FAILURE; COMPLICATION; FEMALE; MALE; TREATMENT OUTCOME;

ADULT; ANEMIA; ANTI-INFLAMMATORY AGENTS; FEMALE; HUMANS; MALE; PENTOXIFYLLINE; PHOSPHODIESTERASE INHIBITORS; RENAL INSUFFICIENCY, CHRONIC; TREATMENT OUTCOME;

EID: 84941960462     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0134104     Document Type: Article

References (32)

1. Stauffer ME, Fan T. Prevalence of anemia in chronic kidney disease in the United States. PloS one. 2014; 9(1):e84943. doi: 10.1371/journal.pone.0084943 PMID: 24392162; PubMed Central PMCID: PMC3879360.
2. Tonelli M, Winkelmayer WC, Jindal KK, Owen WF, Manns BJ. The cost-effectiveness of maintaining higher hemoglobin targets with erythropoietin in hemodialysis patients. Kidney Int. 2003; 64(1):295-304. doi: 10.1046/j.1523-1755.2003.00079.x PMID: 12787422.
3. Clement FM, Klarenbach S, Tonelli M, Wiebe N, Hemmelgarn B, Manns BJ. An economic evaluation of erythropoiesis-stimulating agents in CKD. American journal of kidney diseases: the official journal of the National Kidney Foundation. 2010; 56(6):1050-61. doi: 10.1053/j.ajkd.2010.07.015 PMID: 20932621.
4. Szczech LA, Barnhart HX, Inrig JK, Reddan DN, Sapp S, Califf RM, et al. Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. Kidney Int. 2008; 74(6):791-8. doi: 10.1038/ki.2008.295 PMID: 18596733; PubMed Central PMCID: PMC2902279.
5. Solomon SD, Uno H, Lewis EF, Eckardt KU, Lin J, Burdmann EA, et al. Erythropoietic response and outcomes in kidney disease and type 2 diabetes. The New England journal of medicine. 2010; 363 (12):1146-55. doi: 10.1056/NEJMoa1005109 PMID: 20843249.
6. Jennings DL, Williams CT, Morgan JA. Pentoxifylline for the treatment of hemolytic anemia in a patient who developed recurrent gastrointestinal bleeding while on continuous-flow left ventricular assist device support. ASAIO journal. 2013; 59(5):526-7. doi: 10.1097/MAT.0b013e31829f0eb1 PMID: 23896772.
7. Assem M, Yousri M. Impact of pentoxifylline and vitamin e on ribavirin-induced haemolytic anaemia in chronic hepatitis C patients: an egyptian survey. International journal of hepatology. 2011; 2011:530949. doi: 10.4061/2011/530949 PMID: 21994862; PubMed Central PMCID: PMC3170830.
8. Raza A, Qawi H, Andric T, Dar S, Lisak L, Huang RW, et al. Pentoxifylline, Ciprofloxacin and Dexamethasone Improve the Ineffective Hematopoiesis in Myelodysplastic Syndrome Patients; Malignancy. Hematology. 2000; 5(4):275-84. PMID: 11399622.
9. Sherer JT, Glover PH. Pentoxifylline for sickle-cell disease. The Annals of pharmacotherapy. 2000; 34 (9):1070-4. PMID: 10981255.
10. Rho M. Do pentoxifylline and ascorbic acid improve erythropoiesis stimulating agent resistance? Semin Dial. 2011; 24(4):378-9. Epub 2011/08/02. doi: 10.1111/j.1525-139X.2011.00894.x PMID: 21801213.
11. National Kidney F. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. American journal of kidney diseases: the official journal of the National Kidney Foundation. 2002; 39(2 Suppl 1):S1-266. PMID: 11904577.
12. Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC medical research methodology. 2005; 5:13. doi: 10.1186/1471-2288-5-13 PMID: 15840177; PubMed Central PMCID: PMC1097734.
13. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. Bmj. 2003; 327(7414):557-60. doi: 10.1136/bmj.327.7414.557 PMID: 12958120; PubMed Central PMCID: PMC192859.
14. Cooper A, Mikhail A, Lethbridge MW, Kemeny DM, Macdougall IC. Pentoxifylline improves hemoglobin levels in patients with erythropoietin-resistant anemia in renal failure. Journal of the American Society of Nephrology. 2004; 15(7):1877-82. PMID: 15213276.
15. Ferrari P, Mallon D, Trinder D, Olynyk JK. Pentoxifylline improves haemoglobin and interleukin-6 levels in chronic kidney disease. Nephrology (Carlton, Vic). 2010; 15(3):344-9. Epub 2010/05/18. doi: 10. 1111/j.1440-1797.2009.01203.x PMID: 20470305.
16. Mora-Gutierrez JM, Ferrer-Nadal A, Garcia-Fernandez N. Effect of pentoxifylline on anaemia control in haemodialysis patients: retrospective observational case-control study. Nefrologia. 2013; 33(4):524-31. Epub 2013/07/31. doi: 10.3265/Nefrologia.pre2013.Apr.11654 PMID: 23897184.
17. Mohammadpour AH, Nazemian F, Khaiat MH, Tafaghodi M, Salari P, Charkazi S, et al. Evaluation of the effect of pentoxifylline on erythropoietin-resistant anemia in hemodialysis patients. Saudi journal of kidney diseases and transplantation: an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia. 2014; 25(1):73-8. Epub 2014/01/18. PMID: 24434385.
18. Navarro JF, Mora C, Garcia J, Rivero A, Macia M, Gallego E, et al. Effects of pentoxifylline on the haematologic status in anaemic patients with advanced renal failure. Scandinavian journal of urology and nephrology. 1999; 33(2):121-5. Epub 1999/06/09. PMID: 10360454.
19. Perkins RM, Aboudara MC, Uy AL, Olson SW, Cushner HM, Yuan CM. Effect of pentoxifylline on GFR decline in CKD: a pilot, double-blind, randomized, placebo-controlled trial. American journal of kidney diseases: the official journal of the National Kidney Foundation. 2009; 53(4):606-16. Epub 2009/02/14. doi: 10.1053/j.ajkd.2008.11.026 PMID: 19216016.
20. González-Espinoza L, Rojas-Campos E, Medina-Pérez M, Peña-Quintero P, Gómez-Navarro B, Cueto-Manzano AM. Pentoxifylline decreases serum levels of tumor necrosis factor alpha, interleukin 6 and C-reactive protein in hemodialysis patients: results of a randomized double-blind, controlled clinical trial. Nephrology, dialysis, transplantation [Internet]. 2012; 27(5):[2023-8 pp.]. Available from: http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/324/CN-00882324/frame.html.
21. Mortazavi M, Seyrafian S, Taheri S, Nasiri R, Dolatkhah S, Naini AE, et al. Role of pentoxifylline in treatment of anemic patients suffering chronic hemodialysis: a randomized clinical trial. Med Arh. 2012; 66 (2):84-6. Epub 2012/04/11. PMID: 22486134.
22. Rattanasompattikul M, Molnar MZ, Lee ML, Dukkipati R, Bross R, Jing J, et al. Anti-Inflammatory and Anti-Oxidative Nutrition in Hypoalbuminemic Dialysis Patients (AIONID) study: results of the pilot-feasibility, double-blind, randomized, placebo-controlled trial. J Cachexia Sarcopenia Muscle. 2013; 4 (4):247-57. Epub 2013/09/21. doi: 10.1007/s13539-013-0115-9 PMID: 24052226; PubMed Central PMCID: PMCPmc3830006.
23. Antunes SA, Vilela RQ, Vaz JD, Canziani MEF. Pentoxifylline does not alter the concentration of hepcidin in chronic kidney disease patients undergoing hemodialysis. International journal of artificial organs [Internet]. 2014; 37(7):[521-8 pp.]. Available from: http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/416/CN-01041416/frame.html.
24. Johnson DW, Pascoe EM, Badve SV, Dalziel K, Cass A, Clarke P, et al. A randomized, placebo-controlled trial of pentoxifylline on erythropoiesis-stimulating agent hyporesponsiveness in anemic patients with CKD: the Handling Erythropoietin Resistance With Oxpentifylline (HERO) trial. American journal of kidney diseases: the official journal of the National Kidney Foundation. 2015; 65(1):49-57. Epub 2014/08/15. doi: 10.1053/j.ajkd.2014.06.020 PMID: 25115616.
25. Betjes MG. Immune cell dysfunction and inflammation in end-stage renal disease. Nature reviews Nephrology. 2013; 9(5):255-65. doi: 10.1038/nrneph.2013.44 PMID: 23507826.
26. Kreth S, Ledderose C, Luchting B, Weis F, Thiel M. Immunomodulatory properties of pentoxifylline are mediated via adenosine-dependent pathways. Shock. 2010; 34(1):10-6. doi: 10.1097/SHK. 0b013e3181cdc3e2 PMID: 19997047.
27. Vilayur E, Harris DC. Emerging therapies for chronic kidney disease: what is their role? Nature reviews Nephrology. 2009; 5(7):375-83. doi: 10.1038/nrneph.2009.76 PMID: 19455178.
28. Horl WH. Anaemia management and mortality risk in chronic kidney disease. Nature reviews Nephrology. 2013; 9(5):291-301. doi: 10.1038/nrneph.2013.21 PMID: 23438972.
29. Champion S, Lapidus N, Cherie G, Spagnoli V, Oliary J, Solal AC. Pentoxifylline in heart failure: a meta-analysis of clinical trials. Cardiovascular therapeutics. 2014; 32(4):159-62. doi: 10.1111/1755- 5922.12076 PMID: 24758396.
30. Pammi M, Haque KN. Pentoxifylline for treatment of sepsis and necrotizing enterocolitis in neonates. The Cochrane database of systematic reviews. 2015; 3:CD004205. doi: 10.1002/14651858. CD004205.pub3 PMID: 25751631.
31. Babitt JL, Lin HY. Mechanisms of anemia in CKD. J Am Soc Nephrol. 2012; 23(10):1631-4. doi: 10. 1681/ASN.2011111078 PMID: 22935483; PubMed Central PMCID: PMC3458456.
32. Cooper AC, Mikhail A, Lethbridge MW, Kemeny DM, Macdougall IC. Increased expression of erythropoiesis inhibiting cytokines (IFN-gamma, TNF-alpha, IL-10, and IL-13) by T cells in patients exhibiting a poor response to erythropoietin therapy. J Am Soc Nephrol. 2003; 14(7):1776-84. PMID: 12819237.